XML 20 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023   10,143      
Beginning balance at Dec. 31, 2023 $ 67,222 $ 1 $ 1,003,718 $ (473) $ (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,166   4,166    
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 (in shares)   10,573      
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 119,361 $ 1 119,360    
Common stock issued upon release of restricted stock units (in shares)   25      
Common stock issued upon exercise of stock options (in shares)   14      
Common stock issued upon exercise of stock options 139   139    
Foreign currency translation adjustments (19)     (19)  
Unrealized (loss) gain on marketable securities, net (41)     (41)  
Net loss (27,147)       (27,147)
Ending balance (in shares) at Mar. 31, 2024   20,755      
Ending balance at Mar. 31, 2024 163,681 $ 2 1,127,383 (533) (963,171)
Beginning balance (in shares) at Dec. 31, 2023   10,143      
Beginning balance at Dec. 31, 2023 67,222 $ 1 1,003,718 (473) (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Foreign currency translation adjustments 7        
Net loss (89,996)        
Ending balance (in shares) at Sep. 30, 2024   20,801      
Ending balance at Sep. 30, 2024 108,270 $ 2 1,134,556 (268) (1,026,020)
Beginning balance (in shares) at Mar. 31, 2024   20,755      
Beginning balance at Mar. 31, 2024 163,681 $ 2 1,127,383 (533) (963,171)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 3,945   3,945    
Common stock issued upon release of restricted stock units (in shares)   2      
Common stock issued under employee stock purchase plan (in shares)   44      
Common stock issued under employee stock purchase plan 264   264    
Foreign currency translation adjustments 10     10  
Unrealized (loss) gain on marketable securities, net (2)     (2)  
Net loss (30,498)       (30,498)
Ending balance (in shares) at Jun. 30, 2024   20,801      
Ending balance at Jun. 30, 2024 137,400 $ 2 1,131,592 (525) (993,669)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,964   2,964    
Foreign currency translation adjustments 16     16  
Unrealized (loss) gain on marketable securities, net 241     241  
Net loss (32,351)       (32,351)
Ending balance (in shares) at Sep. 30, 2024   20,801      
Ending balance at Sep. 30, 2024 108,270 $ 2 1,134,556 (268) (1,026,020)
Beginning balance (in shares) at Dec. 31, 2024   20,848      
Beginning balance at Dec. 31, 2024 70,714 $ 2 1,138,070 (407) (1,066,951)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,778   2,778    
Common stock issued upon release of restricted stock units (in shares)   43      
Foreign currency translation adjustments 2     2  
Unrealized (loss) gain on marketable securities, net (53)     (53)  
Net loss (47,019)       (47,019)
Ending balance (in shares) at Mar. 31, 2025   20,891      
Ending balance at Mar. 31, 2025 26,422 $ 2 1,140,848 (458) (1,113,970)
Beginning balance (in shares) at Dec. 31, 2024   20,848      
Beginning balance at Dec. 31, 2024 70,714 $ 2 1,138,070 (407) (1,066,951)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Foreign currency translation adjustments 26        
Net loss (143,862)        
Ending balance (in shares) at Sep. 30, 2025   21,999      
Ending balance at Sep. 30, 2025 (55,653) $ 2 1,155,598 (440) (1,210,813)
Beginning balance (in shares) at Mar. 31, 2025   20,891      
Beginning balance at Mar. 31, 2025 26,422 $ 2 1,140,848 (458) (1,113,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,423   2,423    
Common stock issued upon release of restricted stock units (in shares)   34      
Common stock issued under employee stock purchase plan (in shares)   57      
Common stock issued under employee stock purchase plan 120   120    
Foreign currency translation adjustments 18     18  
Unrealized (loss) gain on marketable securities, net (11)     (11)  
Net loss (49,191)       (49,191)
Ending balance (in shares) at Jun. 30, 2025   20,982      
Ending balance at Jun. 30, 2025 (20,219) $ 2 1,143,391 (451) (1,163,161)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,349   2,349    
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 (in shares)   1,008      
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 9,858   9,858    
Common stock issued upon release of restricted stock units (in shares)   9      
Foreign currency translation adjustments 6     6  
Unrealized (loss) gain on marketable securities, net 5     5  
Net loss (47,652)       (47,652)
Ending balance (in shares) at Sep. 30, 2025   21,999      
Ending balance at Sep. 30, 2025 $ (55,653) $ 2 $ 1,155,598 $ (440) $ (1,210,813)